Roche and GSK ink new deal, settle old score

Roche and GlaxoSmithKline have inked a licensing deal for the obesity drug Orlistat while agreeing to drop litigation over a separate licensing deal. Roche provided an unspecified settlement to GSK. GSK gained the exclusive non-prescription rights to Orlistat outside of the U.S. and Japan. And all claims regarding the marketing of Carvedilol were dropped.

- here's the MarketWatch report on the settlement